AgingResearch.NewsJoin free

Nicotinamide mononucleotide + combination antiretroviral therapy

Intervention

1 paper studies it2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 2 countries
  • Funder: University of Hong Kong
  • Animals1

Outcomes

2

Immune response

downin mice1

1 study

  1. Nicotinamide mononucleotide + combination antiretroviral therapy inhibits immune response in mice.

    “correlated with suppressed hyperactivation of CD4+ T cells”

    Animalsin HIV-1-infected humanized mice

    Nicotinamide mononucleotide impacts HIV-1 infection by modulating immune activation in T lymphocytes and humanized mice

    EBioMedicineNov 17, 2023

More on Immune response

CD4+ T cell count

upin mice1

1 study

  1. Nicotinamide mononucleotide + combination antiretroviral therapy increases CD4+ T cell count in mice.

    “the frequency of CD4+ T cells was reconstituted significantly by combined cART and NMN treatment as compared with cART or NMN alone”

    Animalsin HIV-1-infected humanized mice compared with cART or NMN alone

    Nicotinamide mononucleotide impacts HIV-1 infection by modulating immune activation in T lymphocytes and humanized mice

    EBioMedicineNov 17, 2023

More on CD4+ T cell count

Latest

Related